VivoSeq
Other

HBV

0

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

HBV is an early-stage landscape with 0 programs across 5 companies. The most active players are GSK, Enyo Pharma, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalE

Enyo Pharma

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalD

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed7 · 64%
Terminated1 · 9%
Unknown status1 · 9%
Not yet recruiting1 · 9%
Withdrawn1 · 9%

Clinical Trials

Trial Activity

11 trials

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens
Not yet recruiting·HHuashan Hospital·N/A·NCT06923280·30 enrolled
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
Completed·EEnyo Pharma·Phase 1·NCT03272009·73 enrolled
Optimizing HBV Management During Anti-CD20 Antibodies
Completed·TThe University of Hong Kong·N/A·NCT03155984·83 enrolled
Study of Safety and Tolerability of DCR HBVS
Completed·DDicerna Pharmaceuticals, Inc., a Novo Nordisk company·Phase 1·NCT03772249·82 enrolled
Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib
Completed·GSK logoGSK·Phase 3·NCT00473668·300 enrolled
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2/3·NCT00051038
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
Completed·GSK logoGSK·Phase 3·NCT00317109·168 enrolled
Effects of Antiviral Therapy on HBV Reactivation
Completed·GGuangxi Medical University·Phase 2/3·NCT02829359·200 enrolled
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
Terminated·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT00447902·11 enrolled
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
Withdrawn·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04046107
NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC
Unknown status·NNational Taiwan University Hospital·N/A·NCT04405011·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)